So how do we get from slightly increased numbers of uncommon events in a single study (ORAL Surveillance)? Regulators think differently to us, which partly is the difficulty of a restrictive warning. So being the Aussie I am, I asked - does it pass the 'pub test'? 4/ #EULAR2024 https://t.co/Ih9H87wH22

• https://twitter.com/drdavidliew/status/1801144553241797037/photo/1
• https://twitter.com/drdavidliew/status/1801144553241797037/photo/1
• https://twitter.com/drdavidliew/status/1801144553241797037/photo/1
• https://twitter.com/drdavidliew/status/1801144553241797037/photo/1

Having said that, the EMA warning has elements making it extremely tough: - still very broad criteria that capture 80% of people who were starting JAKi - the need for "no suitable treatment alternatives" before using a JAKi, right across all diseases (not just RA) 3/ #EULAR2024 https://t.co/IsrYO7qzqM

• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1
• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1
• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1

So I think there is plenty we could do instead. better regulation better risk stratification better counselling better risk factor management (and definitely read this if you want to be a good clinician: https://t.co/RA6ktQB7gm) 18/ #EULAR2024 https://t.co/bC5nmi8SoM

• The Art of Communicating Risk and Benefit to Promote Shared Decision‐Making, In…
• https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
• https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
• https://twitter.com/drdavidliew/status/1801144689774735739/photo/1
• https://twitter.com/drdavidliew/status/1801144689774735739/photo/1

My friend the late, great @philipcrobinson and I wrote @TheLancetRheum about what we could learn from COVID about preventative medicine. https://t.co/55j8rduvyn It's worth us thinking how we can do better by our patients. 18/ #EULAR2024 https://t.co/zlDKYngsu0

• Preventive medicine in rheumatology: COVID-19 and its lessons for better health…
• https://twitter.com/drdavidliew/status/1801144698007892437/photo/1

Here's my 'pub test' for whether the warning is appropriate. And, debate aside, I do believe that it behoves any regulator to consider the unintended consequences of their regulation, because regulation has real consequences. 5/ #EULAR2024 https://t.co/aurbAwgl9P

• https://twitter.com/drdavidliew/status/1801144562095940083/photo/1

The original direct comparison study! https://t.co/hqrPKfNW1y

• https://twitter.com/bella_mehta/status/1800893238737527096/photo/1

https://t.co/H8TijO4UUV

• https://twitter.com/bella_mehta/status/1800894662221435004/photo/1
• https://twitter.com/bella_mehta/status/1800894662221435004/photo/1
• https://twitter.com/bella_mehta/status/1800894662221435004/photo/1

Computer vision/ image analysis is performing very well in rheumatology and can extend help to low resource settings easily! #EULAR2024 https://t.co/8doM7foriM

• https://twitter.com/bella_mehta/status/1800896321903313106/photo/1

SLE RPI may be used more frequently and can connect the digital dots! @RheumNow https://t.co/UdVIyZJhJV

• https://twitter.com/bella_mehta/status/1800896319235731601/photo/1

Deep learning models are detecting CPPD in radiographs pretty well!! Abst#0112 #EULAR2024 presented by @ThomasHugle ...@RheumNow https://t.co/9z3VVbyyh0

• https://twitter.com/bella_mehta/status/1801174052075405753/photo/1
• https://twitter.com/bella_mehta/status/1801174052075405753/photo/1
• https://twitter.com/bella_mehta/status/1801174052075405753/photo/1

Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi 👋🏼 😃 Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY

• https://twitter.com/Yuz6Yusof/status/1800771327248535739/photo/1

#EULAR2024 OP0077 Please find an interview with my dear colleague @edvital on the importance of achieving and sustaining B cell depletion for improved clinical response in #lupus #SLE @RheumNow https://t.co/4rTtFWxSvs https://t.co/4esoFTsgzC

• Does B Cell Depletion Matter?
• https://twitter.com/Yuz6Yusof/status/1801126042578395601/photo/1

#EULAR2024 OP0124 EULAR recommended target oral Pred =<5mg/d. Should the threshold of LLDAS be changed to LLDAS5? Multicentre study showed the protection gained from mortality, irreversible organ damage accrual and flare was no different btw the two targets @RheumNow #EULARBEST https://t.co/GbP25tTmX8

• https://twitter.com/Yuz6Yusof/status/1801176143971647832/photo/1
• https://twitter.com/Yuz6Yusof/status/1801176143971647832/photo/1

#EULAR2024 OP0145 Can we reclassify people with ANA+ RMD to improve clinical outcomes & stratify for basket trials? Deep machine learning identified distinct classes of ANA-RMD with distinct phenotypes & predicted long-term outcomes better than the legacy diagnoses @RheumNow https://t.co/W2hmmj0v8Y

• https://twitter.com/Yuz6Yusof/status/1801179216769139144/photo/1

#EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2

• https://twitter.com/Yuz6Yusof/status/1801182856523251734/photo/1